Thalidomide-O-amido-PEG4-propargyl

Thalidomide-O-amido-PEG4-propargyl, is designed to connect an E3 ligase-binding warhead to a target-binding ligand through a PEG-based, amide-linked spacer terminating in a propargyl handle. Its flexible, hydrophilic architecture can improve solubility and conformational adaptability in ternary-complex formation. The propargyl functionality enables efficient bioconjugation strategies commonly used in PROTAC assembly, and the subsequent sections below describe its structure and practical reactivity considerations in detail.

Structure: The linker contains a PEG-based polyether chain providing hydrophilicity and conformational flexibility, coupled through an O-amide linkage to a thalidomide-derived moiety. It features amide and ether linkages along with an alkynyl (propargyl) terminus suitable for click-type coupling. Overall, it is a neutral, polar organic scaffold.

Reactivity: The terminal propargyl group supports copper-catalyzed azide–alkyne cycloaddition (CuAAC) for attaching azide-functional partners during PROTAC construction. Typical conditions employ a Cu(I) source generated in situ, an appropriate ligand to stabilize copper, and aqueous/organic mixed solvents compatible with biomolecular conjugation. The reaction proceeds via formation of a copper-acetylide intermediate followed by cycloaddition to the azide, yielding a stable triazole linkage.